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ABSTRACT
Introduction: The mainstay treatment for reducing the
symptoms of angina and long-term risk of heart
attacks in patients with heart disease is stent
implantation in the diseased coronary artery. While this
procedure has revolutionised treatment, the incidence
of secondary events remains a concern. These repeat
events are thought to be due, in part, to continued
enhanced platelet reactivity, endothelial dysfunction
and ultimately restenosis of the stented artery. In this
study, we will investigate whether a once a day
inorganic nitrate administration might favourably
modulate platelet reactivity and endothelial function
leading to a decrease in restenosis.
Methods and design: NITRATE-OCT is a double-
blind, randomised, single-centre, placebo-controlled
phase II trial that will enrol 246 patients with stable
angina due to have elective percutaneous coronary
intervention procedure with stent implantation. Patients
will be randomised to receive 6 months of a once a
day dose of either nitrate-rich beetroot juice or nitrate-
deplete beetroot juice (placebo) starting up to 1 week
before their procedure. The primary outcome is
reduction of in-stent late loss assessed by quantitative
coronary angiography and optical coherence
tomography at 6 months. The study is powered to
detect a 0.22±0.55 mm reduction in late loss in the
treatment group compared with the placebo group.
Secondary end points include change from baseline
assessment of endothelial function measured using
flow-mediated dilation at 6 months, target vessel
revascularisation (TVR), restenosis rate (diameter>50%)
and in-segment late loss at 6 months, markers of
inflammation and platelet reactivity and major adverse
cardiac events (ie, myocardial infarction, death,
cerebrovascular accident, TVR) at 12 and 24 months.
Ethics and dissemination: The study was approved
by the Local Ethics Committee (15/LO/0555). Trial
results will be published according to the CONSORT
statement and will be presented at conferences and
reported in peer-reviewed journals.
Trial registration numbers: NCT02529189 and
ISRCTN17373946, Pre-results.
INTRODUCTION
Coronary heart disease is the single most
common cause of death in the UK causing 1
in 7 and 1 in 10 deaths in men and women,
respectively (http://www.bhf.org.uk).
Presently, timely percutaneous coronary
intervention (PCI) with stent implantation
remains the most effective treatment strategy
for limiting events and infarct size following
an acute myocardial infarction, preserving
Strengths and limitations of this study
▪ This is the first randomised-controlled trial
assessing the use of dietary nitrate to reduce the
rates of restenosis in patients undergoing percu-
taneous coronary intervention for stable angina.
▪ This study will determine the potential of dietary
nitrate as adjunctive therapy in patients with
stable angina.
▪ This study will determine whether a sustained
elevation of nitrite, using a safe method of
administration, might cause a decrease in the
extent of restenosis following stent implantation
and in this way reduce the need for repeat
intervention.
▪ This is a single-centre study; therefore, the
applicability of the results to other units would
be affected.
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left ventricular ejection fraction and improving clinical
outcomes.1–4 However, despite these advances,3–5 sub-
stantial mortality6 and morbidity rates persist with
respect to longer term outcome. In simple lesions,
restenosis rates have been estimated to be <5% at 1 year
but at 5 years, repeat intervention rates are ∼10%.7
However, in more complex lesions, restenosis has been
documented at 10% within 2 years.8 In addition, recent
assessments of patients undergoing PCI (∼50% with
stable angina) demonstrate that in-stent thrombosis,
despite antiplatelet therapy, remains a concern, with
recent calls urging identiﬁcation of more effective and
safer antiplatelet therapy.9 10 A major determinant of
prognosis after treatment is the reocclusion of the
affected arteries. A number of speciﬁc phenomena have
been linked with reocclusion including persistent endo-
thelial dysfunction, increased platelet reactivity and
restenosis. Therefore, strategies that might limit or
indeed correct these phenomena have clear therapeutic
potential.
In the healthy cardiovascular system, tonically gener-
ated nitric oxide (NO), produced via the conventional
L-arginine/NO synthesis pathway, plays an essential role
in maintaining homoeostasis and in sustaining healthy
cardiac function, perfusion and cardioprotection.11 12 In
patients with coronary artery disease, a generalised
‘endothelial dysfunction’ which is characterised by deﬁ-
cient endothelium-derived bioavailable NO exists; the
extent of which is correlated with severity of coronary
artery disease.13 The cardioprotective effects of NO
relate to a number of actions including its potent vaso-
dilator effect in the ischaemic myocardium,14 allowing
for essential perfusion of injured tissue, its anti-
inﬂammatory effects repressing leucocyte recruitment,15
its antiplatelet effects14 16 17 and its antiproliferative
inﬂuence over vascular smooth muscle.14 18 Thus, the
replacement of this ‘lost’ NO represents an approach
that might offer therapeutic utility.
A potential solution for elevating endogenous NO
levels lies in the chemical reduction of inorganic nitrite
(NO2
−) to NO. Indeed, nitrite-derived NO protects
against myocardial ischaemia/reperfusion injury in pre-
clinical models,19 20 attenuates vascular smooth muscle
cell proliferation in a model of balloon injury in rats,21
protects against endothelial dysfunction22 23 and attenu-
ates platelet reactivity in healthy volunteers and patients
with hypercholesterolaemia.24 25 Importantly, NO2
− does
not suffer tachyphylaxis and its function is not depend-
ent on metabolising enzymes that are dysfunctional in
cardiovascular disease as with organic nitrates; factors
that are major limiting issues underlying the difﬁculties
with organic nitrates experienced within the clinical
setting.26
Recently, a simple and safe method has been identi-
ﬁed for elevating circulating nitrite levels via inorganic
nitrate supplementation through consumption of vegeta-
bles (eg, beetroot). In healthy volunteers and patients
with cardiovascular disease dietary nitrate, in the form
of beetroot juice, causes dose-dependent rises in circu-
lating nitrite levels associated with improvement in endo-
thelial dysfunction, and suppressed platelet reactivity
assessed ex vivo.23–25 27 Furthermore, there have now
been several studies in patients demonstrating the bene-
ﬁts of inorganic nitrate, administered either through the
use of nitrate-rich beetroot juice or through provision of
a nitrate salt dose, with respect to improvements in
maximal oxygen consumption and diastolic function in
heart failure28 29 as well as reduction in platelet reactivity
and improvements in endothelial function in patients
with hypercholesterolaemia25 that importantly could
have direct relevance for patients with angina undergo-
ing elective intervention.
Thus, together all of the above issues support the
rationale for further exploration of potential approaches
based on elevation of circulating nitrite levels that might
reduce the burden of revascularisation on the National
Health Service (NHS), and underline the rationale for
the clinical trial described here.
METHODOLOGY
Trial objectives
Aims of research: The trial is designed to test whether
dietary nitrate ingestion in addition to conventional
therapy has beneﬁcial effects in patients with stable
angina. In particular, the aim is to investigate whether
dietary nitrate leads to antiplatelet effects, improvement
of endothelial function and improvements of intimal
hyperplasia thereby possibly resulting in reductions of
restenosis rates post-PCI and stent implantation.
Participant selection
This is a single-centre trial and patients will be recruited
at Barts Health NHS Trust within the Barts and the
London Heart Attack Centre, based at the Barts Heart
Centre, St Bartholomew’s Hospital. In addition, we will
identify patients from King George Hospital which is
part of Barking, Havering and Redbridge NHS Trust.
Original hypothesis
Dietary nitrate ingestion, in addition to conventional
therapy, improves vascular function in patients with
stable angina undergoing PCI.
Speciﬁcally, the aims of the study are:
1. To determine whether dietary nitrate might improve
intimal hyperplasia and thereby restenosis rates
post-PCI and stent implantation.
2. To determine whether dietary nitrate ingestion exerts
antiplatelet effects or improvement of endothelial
function and the mechanisms involved in this effect.
Primary end point
The primary end point will be reduction of in-stent late
loss assessed by angiography (quantitative coronary angi-
ography, QCA) at 6±1 months. Assessment of restenosis
will be made by measurement of in-stent late loss
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assessed by angiography and optical coherence tomog-
raphy (OCT) at 6±1 months.
Secondary end points
1. Improvement in endothelial function assessed by
ﬂow-mediated dilation (FMD) of the brachial artery at
6 months compared with preprocedure assessment.
2. Reduction in target vessel revascularisation (TVR),
restenosis rate (diameter >50%) and in-segment late
loss at 6±1 months.
3. Reduction in major adverse cardiac events (ie, myo-
cardial infarction, death,) at 6, 12 and 24 months in
addition to cardiovascular accident and TVR.
4. Reduction in plaque size as assessed using OCT at 6
±1 months.
5. Reduction in inﬂammatory markers and changes in
plasma xanthine oxidoreductase activity, high-
sensitivity C reactive protein, interleukin-6 at 6 and
12 months.
6. Reduction in platelet aggregation ex vivo at 6 and
12 months compared with preprocedure.
Inclusion criteria
1. Patients with stable angina diagnosed by a cardiolo-
gist on optimal medical therapy undergoing angio-
plasty to treat residual symptoms.
2. Aged 18–85.
3. Patients able and willing to give their written
informed consent.
4. Patients undergoing successful PCI procedure.
Exclusion criteria
1. Unstable ischaemic heart disease, with an episode
of chest pain in <24 hours before inclusion into the
study.
2. Patients who have had previous coronary artery
bypass surgery, if they are undergoing angioplasty
within a non-native vessel.
3. Patients undergoing angioplasty with a bioabsorb-
able stent since the stents will likely start dissolving
prior to 6 months and therefore this would con-
found measures of restenosis.
4. Current diagnosis of, or treatment for, malignancy
other than non-melanoma skin cancer.
5. Current life-threatening condition other than vascu-
lar disease that may prevent a participant complet-
ing the study.
6. Use of an investigational device or investigational
drug within 30 days or ﬁve half-lives (whichever is
the longer) preceding the ﬁrst dose of study
medication.
7. Patients considered unsuitable to participate by the
research team (eg, due to medical reasons, labora-
tory abnormalities or participant’s unwillingness to
comply with all study-related procedures).
8. Severe acute infection, or signiﬁcant trauma (burns,
fractures).
9. Pregnancy tested by urine human chorionic
gonadotropin measurement.
10. History of alcohol or drug abuse within the past
6 months.
11. A history of heart failure New York Heart
Association (NYHA) class 3–4 or severe left ventricu-
lar dysfunction left ventricular ejection fraction
<30% regardless of symptom status.
12. Systemic autoimmune disease such as rheumatoid
arthritis, connective tissue disease or other condi-
tions known to be associated with chronic inﬂamma-
tion such as inﬂammatory bowel disease.
13. Patients who have donated >500 mL blood within
56 days prior to study medication administration.
14. Anaemia with haemoglobin <10 g/dL, or any other
known blood disorder or signiﬁcant illness that may
affect platelet function, and coagulation.
15. A history of chronic viral hepatitis (including pres-
ence of hepatitis B surface antigen or hepatitis C
antibody or other chronic hepatic disorder) or HIV.
16. Abnormal liver function due to acute or chronic liver
conditions 3×upper limit of normal at screening.
17. Renal impairment with creatinine clearance (esti-
mated glomerular ﬁltration rate) of 35 mL/min at
screening.
18. If patients are on mouthwash, they must be willing
to stop using this at least 1 week before the start of
the study and throughout the duration that they are
involved in the study.
Study design and intervention
This is a prospective double-blind, placebo-controlled,
clinical study. A total of 246 patients (male and female,
age 18–85) with stable angina as per requirements indi-
cated above will be recruited. Figure 1 shows a summary
of the study scheme. Since patients with diabetes are at
high risk of developing restenosis, these patients will also
be included in our study with stratiﬁcation in both
groups. Patients will be stratiﬁed according to the type
of stent (ie, bare metal stent (BMS) or drug-eluting
stent (DES)) as both these groups have differing
characteristics resulting in differing rates of restenosis.
Follow-up will take place in the Clinical Trials Unit,
William Harvey Heart Centre. The patients will inevit-
ably have other comorbidities that include raised blood
pressure and hypercholesterolaemia, and these will be
recorded. Patients will be block randomised (using an
online randomisation database) to receive 70 mL of a
beetroot juice concentrate containing ∼5 mmol nitrate
or nitrate-depleted placebo juice concentrate ( James
White Drinks, UK) control. The volunteers will start
taking their daily dose at home the day before the
scheduled angioplasty and continue daily for 6 months.
Patients will be advised to take their dose of juice at the
same time each day, preferably in the morning with
their breakfast. Patients will also be provided with
dietary advice in relation to the caloriﬁc content of the
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juice: a daily dose of 70 mL of the juice concentrate
(∼70 g) contains about 100 kcal.
On the day of index procedure, patients will be
treated as per Barts Health Trust protocols. Here, the
patient will arrive to the day case ward in the morning
of the procedure and the senior interventional trainee
registrar and consultant cardiologist will perform the
coronary angiogram. At the time of the procedure, the
operator will determine the route of access (either via
the radial artery or femoral artery) and the consultant
cardiologist will determine the size (width and length)
and type of stent (DES or BMS) that will be inserted.
Following the procedure, the patient will be transferred
back to the day case ward and discharged by either the
nurse in charge or the cardiology registrar depending
on the complexity of the procedure. Patients will be
Figure 1 hsCRP, high-sensitivity C reactive protein; IL-6, interlukin 6; MACE, major adverse cardiac events; NHS, National
Health Service; OCT, optical coherence tomography; PCI, percutaneous coronary intervention; QCA, quantitative coronary
angiography; TVR, target vessel revascularisation; XOR, xanthine oxidoreductase.
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followed up according to the clinical plan suggested by
the consultant cardiologist at the time of the procedure.
Randomisation and blinding process
Patients will be block randomised on a 1:1 basis to
receive either dietary nitrate or placebo, using a binary
random number sequence (http://www.random.org).
Treatment assignment for volunteers in the dietary
nitrate and placebo groups will remain blinded until
data lock and statistical analysis at the end of the study.
If unblinding is required, the chief investigator for the
study will be informed. A list of the unblinded treat-
ments will be kept in a secure location at the the
William Harvey Heart Centre. The unblinding proced-
ure will be available at all times (24 hours day/7 days a
week).
Methods to be used
Blood, saliva and urine analysis
In this study, blood samples will be taken for the assess-
ment of platelet reactivity, and NO level determination
from the venous side of the circulation from an arm
vein using a yellow butterﬂy needle (19 gauge) while the
participant lies on a comfortable couch. In this study
protocol on visit 2, they will have one such blood test
before starting the treatment or placebo juice. They will
have a further blood test at visit 3 (6 months—prior to
angiogram and OCT) and visit 5 (12 months). Blood
samples will be centrifuged immediately for platelet
reactivity experiments and plasma and red blood cell
storage only for the purposes of making biochemical
measurements (eg, nitrate/nitrite/cyclic guanosine
monophosphate) and will be discarded once used.
Saliva and urine will be collected in a falcon tube at
the time of visits and stored for purposes of measuring
nitrate/nitrite and then discarded. Some saliva will be
centrifuged and a pellet generated. This pellet contains
oral bacteria that have dislodged from the oral cavity.
This pellet will be frozen for identiﬁcation and analysis
of the oral microbiota by second-generation genome
sequencing at a later date.
The nitrate/nitrite concentrations in saliva, blood and
urine will be determined using the technique of chemi-
luminescence as previously described.30 In brief, total
nitrate and nitrite concentration (termed ‘NOx’) will be
determined by adding samples to 0.1 mol/L vanadium
(III) chloride in 1 M hydrochloric acid reﬂuxing at 95°C
under nitrogen. Nitrite concentration will be deter-
mined by the addition of samples to 0.09 mol/L potas-
sium iodide in a glacial acetic acid under nitrogen at
room temperature. Nitrate concentration will be calcu-
lated by the subtraction of (nitrite) from (NOx). All
measurements of all samples will be conducted by an
individual blinded to the intervention.
Pulse wave analysis and pulse wave velocity
This technique is a non-invasive method to measure
arterial stiffness. A Vicorder device (Skidmore Medical
Limited, Bristol, UK) will be used to simultaneously
record the pulse wave from the carotid and femoral site
using an oscillometric method. A small, inﬂatable neck
pad will be placed directly over a single carotid artery
and secured around the neck by a Velcro tab. A cuff will
be placed around the patient’s ipsilateral upper thigh.
Both carotid and femoral cuffs will be inﬂated automat-
ically to 65 mm Hg and the corresponding oscillometric
signal from each cuff will be digitally analysed to extract
the pulse time delay. The distance between the sternal
notch and the thigh cuff will be measured and used as a
standard estimate for the aortic length. From these mea-
surements, aortic pulse wave velocity (PWV) can be
derived as PWV=aortic distance/pulse time delay.31
These procedures are not uncomfortable and take
∼10 min to complete and will be conducted at visit 2
(baseline), visit 3 (6 months—prior to angiogram and
OCT) and visit 5 (12 months).
Index angiogram
Angiography will be performed at baseline prior to stent
placement and after stent placement prior to comple-
tion of the index PCI procedure. Either the radial or
femoral vascular access may be used for the procedure.
The baseline angiograms of the involved vessel will be
performed in at least two near orthogonal views. Visual
angiographic assessment will be used to determine if the
lesion meets angiographic entry criteria.
Further information collated from the index coronary
angiography procedure will be collected, comprising of
date of the angiogram, vessel dominance, number and
location of diseased vessels, location, presence and sever-
ity of lesions for all 14 segments of the coronary tree
and any complications. The PCI procedure will be com-
pleted according to normal practice by the operator.
Index PCI
Procedural information for the index PCI will include
date of the PCI, which coronary vessels and segments
are treated, diameter, length and type of stent
implanted, the procedural success for each segment, the
adjunctive pharmacological therapy and any complica-
tions and information on lesions not treated will also be
recorded.
Repeat coronary angiography with OCT assessment of
vessel treated PCI
Repeat angiography with OCT will occur 6±1 months
after index PCI. Either radial or femoral access sites can
be used and angiograms of the involved vessel performed
in at least two near orthogonal views. Quantitative angio-
graphic assessment of the involved vessel will be under-
taken to determine late loss. In addition, the same
angiographic images will be recorded as those obtained
post-stent implantation at the time of the index procedure.
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Quantitative coronary angiography
Quantitative analysis will be performed using a Coronary
Angiography Analysis System (Medis, the Netherlands).
There will be automated detection of the boundaries of
a selected coronary vessel segment using digitised and
optically magniﬁed sections of the cine frame. If a
wrong centreline is chosen because of large daughter
branches, then correction is possible manually. The
vessel diameter will be calculated in absolute values
(mm). This will be done using the boundaries of a
section of the contrast catheter and comparing the com-
puted mean catheter diameter in pixels with the known
catheter size in mm. To detect the contours of the
vessel, the user will indicate the vessel by choosing two
centre positions proximal and distal to the area of inter-
est. QCA will be analysed in a blinded fashion by two
experienced and independent cardiologists and adjudi-
cated by a senior cardiologist if there are any discrepan-
cies in the analysis.
All angiographic measurements of the target lesion
will be obtained in the ‘in-stent’ zone, within 5 mm
proximal and distal to each stent edge, and over the
entire segment (‘in-segment’ zone). The following QCA
parameters will be calculated: reference vessel diameter,
minimal lumen diameter, per cent diameter stenosis
(difference between the reference vessel diameter and
minimal lumen diameter/reference vessel diam-
eter×100) and late lumen loss (difference between the
postprocedure and follow-up minimal lumen diameter).
Binary restenosis will be deﬁned as stenosis of 50% or
greater in the target lesion or segment at the 6-month
angiographic follow-up.
Optical coherence tomography
OCT imaging of the previously stented segment with
motorised pull back at 1 mm/s will be undertaken in
all patients at 6±1 months after index PCI. OCT images
will be acquired at 15–30 frames per second (500
angular pixels×250 radial pixels), from a 0.15 mm
micro-optic core, 0.36 mm image wire, displayed with
an inverse gray-scale lookup table, and digitally
archived. OCT images will be analysed by an independ-
ent expert in high-resolution OCT analysis. An auto-
matic analysis with novel dedicated software will be
used for quantitative assessment. The existence of
malapposition will be assessed. The OCT variables
recorded will be endothelial coverage: expressed as per
cent of struts without coverage, neointimal thickness at
6±1 months and stent malapposition deﬁned as struts
with detachment from the vessel ≥110 μm. Finally, OCT
imaging will not be used for clinical decision-making
regarding need for a repeat revascularisation proced-
ure. All repeat revascularisation decisions will be based
on a recurrence of clinic symptoms and/or non-
invasive imaging evidence of myocardial ischaemia and
made by the treating physician.
Flow-mediated dilation
Non-invasive ultrasound assessment of endothelial func-
tion of the brachial artery in participants will be deter-
mined by measurement of FMD. FMD is a non-invasive
method of assessing endothelial function in vivo. It uses
vascular ultrasound to measure the increase in the diam-
eter of the brachial artery in response to increased
ﬂow32 and will be conducted according to published
guidelines.33 Brachial artery diameter in the right arm
will be measured with a high-resolution external vascular
ultrasound Siemens\Acuson Sequoia C256 Colour
Doppler with a 7.0-MHz linear-array transducer sup-
ported by a stereotactic clamp. The vessel will be
scanned in longitudinal section and the centre will be
identiﬁed when the clearest views of the anterior and
posterior artery walls have been obtained. Images will be
magniﬁed with a resolution box function and images of
the brachial artery acquired continuously using semiau-
tomated edge detection software (FMD Studio) and ana-
lysed in real time. Here, an automatic mathematical
contour tracking operator locates and tracks the edges,
supplying information about quality and time course of
measurements in real time.34 Blood ﬂow velocity in the
brachial artery will be recorded continuously throughout
the study with pulsed-wave Doppler. Brachial artery
diameter and blood ﬂow velocity will be measured con-
tinuously for 1 min at baseline, during 5 min of reduced
blood ﬂow (induced by inﬂation to 300 mm Hg of a
pneumatic cuff placed at a site distal to the segment of
artery being analysed), and for a further 5 min during
reactive hyperaemia after cuff release. FMD is deﬁned as
the maximum percentage increase in vessel diameter
during reactive hyperaemia. This procedure will be per-
formed at visit 2 (baseline) and visit 3 (6 months—prior
to angiogram and OCT).
Follow-up
After 2 years, the participant will be contacted by tele-
phone for assessment of major adverse cardiac events
(MACE). The whole duration of the study will be
2 years. Participants have no obligation to complete the
whole study and if they decide to withdraw at any point
then they are free to do so.
End of study definition
The study will end after 2 years after the telephone
follow-up of the last patients. At this time, all the
samples will be analysed.
Statistical analysis
Sample size: In order to achieve an 80% probability that
the study will detect a treatment difference at a two-
sided 5% signiﬁcance level, if the true difference in late
loss between the treatments is 0.22 mm, sample size cal-
culations determined that a total of 246 patients will be
required to enter a two-treatment parallel design study.
This absolute difference is calculated from a mean late
loss of 1.27 mm with an SD of the response variable of
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0.550. These values being the mean and average of the
SDs of 22 trials measuring late loss in drug-eluting and
BMSs described in the review by Mauri et al.35
Recruitment also takes into account an additional 10%
to account for drop-out or withdrawal/non-compliance.
This value is based on previous experience in our unit.
The sample size of 246 enables sufﬁcient power for
estimation of the hard end point of MACE at 6 months.
Very recently, in patients with stable angina who have
undergone elective angioplasty, a remote ischaemic pre-
conditioning intervention resulted in a signiﬁcant reduc-
tion in MACE at 6 months with 4/110 (3.6%) in the
treatment group versus 13/104 (12.5%) in the control
group.36 Using these data as a basis for power calcula-
tions, a total number of 230 patients are needed for
80% power using one-tailed analysis. Thus, to account
for potential loss to follow-up, we will recruit 246
patients in total.
Power calculations for FMD suggest that the above
numbers provide sufﬁcient power for detecting differ-
ences in FMD (n=60). To calculate power, we used data
provided in dietary studies including one demonstrating
improvements in FMD following 6 weeks of artichoke
juice,37 a further chronic study with walnuts38 and one
meta-analysis39 assessing the effects of chronic polyphe-
nol dietary interventions published in 2012. Calculating
an averaged improvement of FMD of 1.1% with no
change in the control and an averaged SD of 1.45
(determined from the average of the above studies) a
total of 30 volunteers would be needed in each group
requiring a total of 60 volunteers. Using our own data
with dietary nitrate in patients with hypercholesterol-
aemia increases of FMD of 1% with an SD of 1.5%,25 a
total of 74 patients are needed for sufﬁcient power. If we
assume a potential 10% drop-out rate, a total of 80
patients are required.
All statistical analyses will be conducted by the trial sta-
tisticians supported by the imperial clinical trials unit.
Data will be analysed on an intention-to-treat basis. We
will also conduct further per-protocol analyses and a sub-
group analysis on patients who are on organic nitrates as
part of their routine therapy, patients on statin therapy
and a comparison of DESs versus BMSs by incorporating
these variables in a Cox regression analysis model.
Ethical considerations
The study protocol and any subsequent amendments,
along with any accompanying material provided to the
patient, in addition to any advertising material, was sub-
mitted by the investigator to an independent Research
Ethics Committee (REC). Written approval from the
Committee was obtained and subsequently submitted to
the sponsor to obtain ﬁnal sponsorship approval and
NHS permissions.
Safety considerations
The intervention is 70 mL of a beetroot juice concen-
trate or nitrate-free placebo juice ( James White Drinks,
UK). The nitrate is extracted using the same extraction
technique used to remove inorganic nitrate from the
general drinking water supplies. There are no known
harmful side effects from these interventions and this
nitrate-free juice is not considered to be a drug or medi-
cine and is classiﬁed as a foodstuff. In addition, several
recent publications using the placebo juice are now
available.40–42 In the unlikely event of an adverse event
(AE) occurring directly as a result of the intervention,
the trial would be stopped.
Safety reporting
An AE if not deﬁned as serious, will be documented in
the participants’ medical notes (where appropriate) and
the case report form (CRF) and followed up by the
research team. Any serious adverse events (SAEs) that
occur will be reported to the sponsor and main REC
where in the opinion of the chief investigator the event
was either ‘related’ (ie, it resulted from administration
of any of the research procedures) and ‘unexpected’
(ie, the type of event is not listed in the protocol as an
expected occurrence).
SAEs that are considered to be ‘related’ and ‘unex-
pected’ will be recorded in the participants’ notes, the
CRF, the sponsor SAE form and reported to the research
ofﬁce of the Trust within 24 hours of research staff being
notiﬁed, and to the main REC within 15 days. The
co-investigators in this study will be authorised to sign
the SAE forms in the absence of the principal investiga-
tor. Since this study will be blinded, the treatment code
for the patient will be broken in the reporting of an
‘unexpected and related’ SAE. This will be performed
by an individual who is independent of the study and
will allow the rest of the research team to remain
blinded. The unblinding of single cases by the principal
investigator in the course of this study will only be per-
formed if necessary for the safety of the trial participant.
Monitoring
Trial Steering Committee
The Trial Steering Committee (TSC) is composed of
three independent experts in the ﬁelds of: pharmacol-
ogy, interventional cardiology and clinical trials along
with the investigators and the data monitor and medical
statistician and one lay member. This committee has
met before patient recruitment and will meet annually
to assess safety, feasibility or any other arising problems
(eg, with recruitment) and their recommendations will
be followed.
Data Safety and Monitoring Board
An independent Data Safety and Monitoring Board
(DSMB) has been formed to monitor patient safety as
the study progresses. The DSMB has been selected by
and communicates directly to the study’s TSC. The com-
mittee includes a consultant cardiologist, an interven-
tional cardiologist and a statistician. The DSMB met
prior to initiation of the clinical study, after the
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recruitment of 10 patients and will meet at three
monthly intervals. The DSMB will have access to
unblinded patient data. If a serious concern with the
safety of the patients in the trial arises, the DSMB may
recommend early termination of the study.
Dissemination
The study will be performed in agreement with the
Declaration of Helsinki and is approved by the Local
Ethics Committee (NRES Committee City Road and
Hampstead: 15/LO/0555). Data collection will be com-
pleted by mid-2018. Primary and secondary analysis will
start immediately after data monitoring is completed;
publications will be prepared for submission in late
2018. The results of the trial will be published according
to the CONSORT statement. Dissemination of results
will focus on publications in peer-reviewed journals, pre-
sentations at national/international cardiology meetings
and NHS groups. In accordance with recommendations,
we have registered NITRATE-OCT with public registries,
the UK Clinical Research Network (Study ID 20060),
http://clinicaltrials.gov (NCT02529189) and Current
Controlled Trials (International Standard Randomised
Controlled Trials No: 17373946).
SUMMARY
There have been no clinical studies investigating the
role of orally ingested nitrate in reducing restenosis in
patients undergoing PCI for stable angina. NITRATE-
OCT study is the ﬁrst clinical study assessing the safety
and efﬁcacy of oral nitrate in a dietary form (beetroot
juice) in this group of patients. This study will determine
the potential of dietary nitrate as adjunctive therapy in
patients with stable angina.
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